NCT07051915尚未招募3 期
Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) - a Pragmatic Randomized Controlled Trial
Ostfold Hospital Trust0 个研究点目标入组 220 人开始时间: 2025年9月15日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 220
- 主要终点
- Efficacy of the oral TPO-RA, Avatrombopag, to Rituximab
研究概览
简要总结
This study is a phase 3 study where eligible patients will be randomized 1:1 to one of two treatment strategies: receiving a thrombopoietin receptor agonist (Avatrombopag), or anti-CD20 (Rituximab).
详细描述
This is a multi-center, international, open label randomized, controlled pragmatic trial consisting of 3 phases:
- First phase extends from randomization to week 28
- Second phase extends from week 28 to 78
- Third phase extends from week 78 to the end of the trial (i.e. the last patient completing week 78)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 years.
- •Diagnosis of primary ITP of less than one-year duration and having a platelet count of < 30 x109/L measured within two weeks prior to inclusion with failure to achieve response or relapse after at least one cycle of dexamethasone (20-40 mg daily for 4 days) or prednisone /prednisolone (1 mg/kg for at least two weeks). Shorter courses or lower doses are allowed if discontinued or modified due to side effects.
- •Clinical need for subsequent platelet elevating therapy assessed by the physician in charge.
- •Signed and dated written informed consent.
排除标准
- •Previous treatment for ITP with: Rituximab, other immune suppressants (including mycophenolate mofetil, azathioprine, cyclosporine), dapsone, danazol, chemotherapy (apart from vincristine as rescue therapy) or splenectomy. Short treatment with any thrombopoietic agent is allowed if given for a limited duration of a maximum of 2 weeks as rescue therapy for quick elevation of platelet count in emergency situations e.g. bleeding.
- •Pregnancy or lactation.
- •Females of child-bearing potential refusing to follow effective contraceptive methods for at least 12 months following the last administration of Rituximab or during treatment with Avatrombopag.
- •Secondary ITP: ITP secondary to lymphoma or chronic lymphocytic leukemia; ITP secondary to the following autoimmune disorders: Systemic Lupus Erythematosus, Antiphospholipid Syndrome, or Common Variable Immune Deficiency; ITP secondary the following viral infections: Human Immunodeficiency Virus or Hepatitis C Virus.
- •Concomitant autoimmune hemolytic anemia.
- •Active hepatitis B virus (positive HBsAg). Patients with HBsAg negative and HBV core antigen antibody positive (HBcAb) should accept to receive entecavir (Baraclude) for 12 months if they will be allocated to Rituximab. Monthly HBV DNA monitoring will be required while on treatment and for the 6 months after the last dose of the study drug.
- •Presence of any serious comorbidity where the condition may worsen by and of the study drugs.
- •Known allergy, sensitivity or contraindication to Rituximab or Avatrombopag.
- •Patients in a severely immune compromised state.
- •Presence of active malignancy unless deemed cured by adequate treatment. Participants with the following neoplastic conditions can be included:
- •Monoclonal gammopathy of undetermined significance (MGUS) or monoclonal B lymphocytosis of undetermined significance (MBUS).
- •Basal/squamous cell carcinoma of the skin
- •Carcinoma in situ of the cervix
- •Carcinoma in situ of the breast
- •Incidental histological finding of prostate cancer (TNM stage T1a or T1b).
- •Patients with history of poor compliance or history of alcohol/drug abuse or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.
研究组 & 干预措施
Avatrombopag
Experimental
Open label, oral Avatrombopag 20 mg tablets taken daily during the first week. Dose tapering period commencing from week 28 for up to 8 weeks.
干预措施: Avatrombopag (Drug)
Avatrombopag
Experimental
Open label, oral Avatrombopag 20 mg tablets taken daily during the first week. Dose tapering period commencing from week 28 for up to 8 weeks.
干预措施: Rituximab (Arm B) (Drug)
Rituximab
Active Comparator
Open label, intravenous infusions of 1000mg Rituximab 2 weeks apart
干预措施: Avatrombopag (Drug)
Rituximab
Active Comparator
Open label, intravenous infusions of 1000mg Rituximab 2 weeks apart
干预措施: Rituximab (Arm B) (Drug)
结局指标
主要结局
Efficacy of the oral TPO-RA, Avatrombopag, to Rituximab
时间窗: Assessed at week 28
To compare the efficacy of the oral TPO-RA, Avatrombopag to Rituximab by measuring the rates of durable responses defined as achieving platelet counts ≥ 50 X109/L in ≥3 of the bi-weekly measurements between weeks 20 and 28 including the last count without having received any other platelet elevating agents after randomization apart from rescue therapy received before end of week 10.
次要结局
- The changes in the disease specific HRQoL(Baseline to weeks 28 and weeks 78)
- Changes in the level of fatigue(Baseline to weeks 28 and weeks 78)
- Rates of Sustained Response Off-Treatment (SROT)(At 78 weeks)
研究者
相似试验
进行中（未招募）
3 期
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal CancerGastric or Gastroesophageal Junction CancerNCT04950322Suzhou Suncadia Biopharmaceuticals Co., Ltd.737
招募中
2 期
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)Metastatic Colorectal CancerNCT04547166Shanghai Henlius Biotech568
招募中
3 期
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerGastric CancerNCT04139135Shanghai Henlius Biotech642
进行中（未招募）
2 期
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsFallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Mucinous AdenocarcinomaRecurrent Fallopian Tube Transitional Cell CarcinomaRecurrent Fallopian Tube Undifferentiated CarcinomaRecurrent Low Grade Fallopian Tube Serous AdenocarcinomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Low Grade Serous AdenocarcinomaRecurrent Ovarian Mucinous AdenocarcinomaRecurrent Ovarian Seromucinous CarcinomaRecurrent Ovarian Transitional Cell CarcinomaRecurrent Ovarian Undifferentiated CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal CarcinomaRecurrent Primary Peritoneal Clear Cell AdenocarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Low Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Transitional Cell CarcinomaRecurrent Primary Peritoneal Undifferentiated CarcinomaRefractory Fallopian Tube Clear Cell AdenocarcinomaRefractory Fallopian Tube Endometrioid AdenocarcinomaRefractory Fallopian Tube High Grade Serous AdenocarcinomaRefractory Fallopian Tube Mucinous AdenocarcinomaRefractory Fallopian Tube Transitional Cell CarcinomaRefractory Fallopian Tube Undifferentiated CarcinomaRefractory Low Grade Fallopian Tube Serous AdenocarcinomaRefractory Ovarian Clear Cell AdenocarcinomaRefractory Ovarian Endometrioid AdenocarcinomaRefractory Ovarian High Grade Serous AdenocarcinomaRefractory Ovarian Low Grade Serous AdenocarcinomaRefractory Ovarian Mucinous AdenocarcinomaRefractory Ovarian Seromucinous CarcinomaRefractory Ovarian Transitional Cell CarcinomaRefractory Ovarian Undifferentiated CarcinomaRefractory Primary Peritoneal Clear Cell AdenocarcinomaRefractory Primary Peritoneal Endometrioid AdenocarcinomaRefractory Primary Peritoneal High Grade Serous AdenocarcinomaRefractory Primary Peritoneal Low Grade Serous AdenocarcinomaRefractory Primary Peritoneal Transitional Cell CarcinomaRefractory Primary Peritoneal Undifferentiated CarcinomaNCT04739800National Cancer Institute (NCI)120
已完成
3 期
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugPsoriatic ArthritisNCT03104374AbbVie642